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Background: Identifying Plasmodium vivax antigen-specific antibodies associated with P. vivax infection and
protective immunity is key to the development of serosurveillance tools and vaccines for malaria. Antibody targets
of P. vivax can be identified by seroepidemiological studies of individuals living in P. vivax-endemic areas, and is
an important strategy given the limited ability to culture P. vivax in vitro. There have been numerous studies
investigating the association between P. vivax antibody responses and P. vivax infection, but there has been no
standardization of results to enable comparisons across populations.
Methods: We performed a systematic review with meta-analysis of population-based, cross-sectional, case–control,
and cohort studies of individuals living in P. vivax-endemic areas. We searched 6 databases and identified 18 studies
that met predefined inclusion and quality criteria, and examined the association between antibody responses to
P. vivax antigens and P. vivax malaria.
Results: The majority of studies were published in South America (all from Brazil) and the rest from geographically
diverse areas in the Asia-Pacific region. Considerable heterogeneity in estimates was observed, but IgG responses
to PvCSP, PvMSP-119, PvMSP-9RIRII, and PvAMA1 were associated with increased odds of P. vivax infection in
geographically diverse populations. Potential sources of heterogeneity included study design, different transmission
intensities and transmigrant populations. Protective associations were observed for antibodies to PvMSP-119,
PvMSP-1NT, PvMSP-3α and PvMSP-9NT antigens, but only in single geographical locations.
Conclusions: This systematic review revealed several antigen-specific antibodies that were associated with active
infection and protective immunity, which may be useful biomarkers. However, more studies are needed on
additional antigens, particularly cohort studies to increase the body of evidence for protective immunity. More
studies representing diverse geographical regions encompassing varying P. vivax endemicities are needed to
validate the generalizability of the findings and to provide a solid evidence base for the use of P. vivax antigens in
vaccines and serosurveillance tools.
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Plasmodium vivax is the most widely distributed species
of human malaria, with an estimated 40% of the world’s
population being at risk of P. vivax infection [1]. The
majority of P. vivax infections occur in Central and
South-East Asia, and there are approximately 80 to 300
million clinical cases of P. vivax malaria each year [1].
Despite the large burden of disease, P. vivax has trad-
itionally been neglected because it has been considered a
relatively benign form of malaria. Now it is recognized
that P. vivax can cause severe disease (similar to that of
Plasmodium falciparum) [2] and, together with increased
recognition of the burden, there are renewed efforts in the
development of P. vivax-specific interventions (that is,
vaccines) and surveillance tools (diagnostics, serosurveil-
lance) to expedite the goal of malaria elimination and
eradication [3,4].
Currently, only two P. vivax vaccine candidates (Pv
Duffy binding protein (PvDBP) and Pv circumsporozoite
protein PvCSP) are in clinical trials (Phase I) compared
with 23 P. falciparum vaccine candidates (including one
in Phase III trials: RTS,S) [5,6]. This may reflect the
previous neglect of P. vivax, the difficulty in maintaining
P. vivax in culture, and the limited animal models of in-
fection currently available. Such technical challenges
have hindered the ability to prioritize P. vivax candidate
antigens against pre-clinical selection criteria, including
knowledge of protein function and antigenic diversity,
and demonstrations that antibodies against an antigen
inhibit growth in vitro or function in other ways, or are
protective in animal models of infection [7]. In the ab-
sence of an in vitro system, P. vivax antigens can be
selected based on P. falciparum homologues and an
additional pre-clinical selection criterion, namely, that
the antigen induces naturally acquired immunity in indi-
viduals living in malaria-endemic areas [7].
In P. vivax-endemic areas, the prevalence and den-
sity of P. vivax infection and the incidence of P. vivax
symptomatic malaria decrease with age [8]. This epide-
miological pattern reflects the acquisition of natural im-
munity that develops after repeated exposure [9]. This
immunity is non-sterilizing and does not protect against
infection, but acts by reducing parasite numbers in the
blood and the subsequent clinical symptoms. Antibodies
are thought to be an important component of naturally
acquired immunity, and are considered to be biomarkers
of both immunity and exposure. Potential antibody tar-
gets include P. vivax antigens expressed on sporozoites
(the pre-erythrocytic liver stage), the invading merozoite
and the surface of infected erythrocytes (erythrocytic
stage) and the gametocyte (sexual stage) [8]. P. vivax
also has an additional dormant stage in the liver, the
hypnozoite, which is believed to be responsible for re-
lapses in P. vivax infection [10].There have been numerous studies investigating as-
sociations between P. vivax immune responses and P.
vivax infection, but there is considerable heterogeneity
between studies, both in terms of methodology and
presentation of results, making cross-study comparison
problematic. Here, we aimed to review and synthesize
the literature, by standardizing analyses and identifying
targets of naturally acquired immunity to P. vivax, which
we have previously done similarly for P. falciparum [11].
There were two key objectives of this study: to deter-
mine antigen-specific antibody responses associated with
infection, and to determine antibody responses associ-
ated with protective immunity. We included cross-
sectional and case–control studies in order to identify
markers of P. vivax infection, and also included cohort
studies, which provide the highest level of evidence to
detect causal effect in observational research, in order to
identify antibody responses that protect against P. vivax
malaria. The overarching aim of the study was to pro-
vide a more comprehensive understanding of antibody-
mediated immunity to P. vivax and, more specifically, to
help inform the development of vaccines and serosur-
veillance tools to facilitate the control, elimination and
eradication of P. vivax.
Methods
The Meta-analysis of Observational Studies in Epidemi-
ology (MOOSE) working group [12] guidelines and the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) specifications were adhered to
in the conducting and reporting of this systematic re-
view and meta-analysis [13]. For a completed PRISMA
checklist, see Additional file 1.
Search methods for identification of studies
PubMed, Web of Science, Scopus, Google Scholar, African
Index Medicus, and the Latin American and Caribbean
Health Sciences Literature (LILACS) databases were
searched for studies published in all years up to and in-
cluding 30 November 2013 that examined the association
of antibody responses to P. vivax antigens with P. vivax
infection or P. vivax malaria. Key words included: malaria,
vivax, plasmodium, immunoglobulin, IgG, antibody, im-
munity, rhoptry, microneme, sporozoite, CSP, circumspor-
ozoite, TRAP, thrombospondin, merozoite, MSP, AMA,
DBP, Duffy binding protein, EBA, EBP, erythrocyte bind-
ing*, EMP, erythrocyte membrane protein, RBL, reti-
culocyte binding like protein, RBP, reticulocyte binding
protein, VSA, variant surface antigen, VIR, gameotocyte,
transmission blocking, Pvs25, ookinete surface protein,
Pvs28, sexual stage surface protein, transmission-blocking
target antigen, and Pvs230. The full search strategy for
one database (PubMed) is provided (see Additional file 2).
The reference lists of the obtained papers were searched
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than English were included, and were translated into
English using online translation applications. A priori,
we did not formally attempt to identify unpublished
population studies because this would have required
us to provide substantial descriptions of the study de-
sign, sample testing, and analysis used in the studies,
and a review of ethical and other issues.Criteria for considering studies
Study designs and study participants
Population-based cross-sectional, case–control, and co-
hort studies, including treatment to re-infection studies,
were included in the systematic review. Randomized
controlled trials and vaccine efficacy trials of blood-stage
vaccines were excluded because rigorous inclusion and
exclusion criteria are applied in these studies, thus the
participants are, typically, not representative of the gen-
eral population. The primary criterion for study inclu-
sion was inclusion of individuals (children, adults, and/
or pregnant women) living in P. vivax-endemic areas.
All geographical locations were included. Studies of the
following types of populations were excluded because
they were unlikely to represent the general population:
populations experiencing epidemic malaria (that is, no
previous exposure to P. vivax); returned travellers; mili-
tary personnel; and populations in which greater than
20% of individuals were transmigrants who had resided
in the area for less than 5 years at the time of sampling.
Studies that included multiple population subsets were
assessed on a sub-population basis to determine eligibi-
lity for inclusion.Antibody measures
Studies that measured total immunoglobulin G (IgG),
total IgM, or IgG subclass (1–4) responses to recombinant
or synthetic defined P. vivax antigens were considered.
Antibody responses to full-length proteins, processing
products, and defined regions of P. vivax antigens from
any life-cycle stage and any subcellular location were also
included. Responses to peptides representing unde-
fined regions or incomplete domains or subdomains
of antigens were excluded, with the exception of pro-
teins or defined domains that could not be expressed
as a single product. In such cases, responses to a
combination of protein fragments representing the
full-length protein or domain were analyzed. For co-
hort studies, if antibody responses were measured at
multiple time points the baseline (that is, time 0), anti-
body responses were analyzed. Data from cohort studies
in which antibody responses were determined after
malariometric measures were excluded.Malaria outcome measures
The following malaria outcome measures were included:
P. vivax infection, high-density P. vivax infection, and
symptomatic P. vivax malaria, using the definitions as
described in the individual studies. In cohort studies,
P. vivax re-infection was also included as an outcome.
Studies in which malariometric measures were deter-
mined retrospectively (for example, where cumulative
history of malaria exposure was the exposure or out-
come of interest) were excluded.
Quality criteria
The minimum quality criteria for inclusion were: con-
firmation of P. vivax parasitemia by light microscopy,
rapid detection kit, or PCR; detection of P. vivax malaria
by active and/or passive case detection; and symptomatic
malaria defined by fever and/or history of fever (within
the past 72 hours) plus P. vivax parasitemia. In studies
in which symptomatic malaria was the outcome of inter-
est, cases of symptomatic malaria in individuals with P.
falciparum and P. vivax co-infection were excluded be-
cause the symptoms could not be attributed exclusively
to one or the other species. Cut-offs for positive anti-
body responses by ELISA had to be defined by the use
of unexposed (malaria-naïve) controls rather than indi-
viduals from the same exposed population found to be
P. vivax-negative at the time of sampling. For treatment
to re-infection studies, if treatment failure was accoun-
ted for, it had to be defined by either genetic analysis
or documented clearance of infection within a speci-
fied time frame appropriate for the chosen antimalar-
ial. In case–control studies, at least one control for
every case had to be recruited from the same popula-
tion (that is, studies that recruited a small number of
laboratory controls for antibody comparison purposes
were excluded).
Selection of studies
Two independent review authors used the inclusion and
exclusion criteria to screen titles and abstracts. The full
text of potentially relevant studies was retrieved and ex-
amined for compliance with the inclusion and exclusion
criteria by the same two review authors independently.
Discrepancies were resolved by discussion with a third
author.
Effort to include all available studies and data
Authors of original studies were contacted if relevant in-
formation on the study population, eligibility criteria, or
key study data were not presented in the published re-
port. For studies in which antibody responses to P. vivax
antigens were described, but no details of P. vivax out-
comes were reported, authors were invited to provide
malariometric data to enable the study to be included in
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or data, the study was classified as not meeting the in-
clusion and/or quality criteria, and was excluded from
the systematic review. Cross-sectional data from cohort
studies was extracted for inclusion in cross-sectional
analyses. In studies in which multiple cross-sectional
surveys were performed in the same population, esti-
mates were reported for individual surveys if the data
were available. For studies in which antibody responses
were analysed as the outcome variable, data were re-
analyzed so that malaria or P. vivax infection was the
outcome variable.Risk of bias in individual studies
At an individual study level, selection bias was assessed
to determine whether participants were representative of
the general population by reviewing individual study
inclusion and exclusion criteria. Selection bias in case–
control studies was assessed by assessing the compa-
rability of cases and controls as part of the systematic
review quality criteria. We excluded case–control studies
if the source population differed between cases and con-
trols, because bias would be introduced into the esti-
mates of the association between P. vivax antibodies and
outcomes. An additional selection bias can occur in
case–control studies when cases and/or controls are se-
lected based on criteria relating to their exposure (that
is, antibody) status or when there are differences in the
reporting of exposure between cases and controls. How-
ever, this is unlikely because immunoassays would be
performed after enrolment into the study. Information
bias (resulting from flaws in measuring antibody and
P. vivax outcome data) are unlikely because antibo-
dies are measured using immunoassays that are stan-
dardized within each study and across outcome groups.
The quality criterion of this review ensured accurate
measurement of P. vivax outcomes, and it is unlikely
that measurement of outcomes would differ depending
on antibody groups. To reduce bias further, we excluded
studies that measured the P. vivax outcome prior to
antibody determination. Although these studies may be
useful in determining markers of exposure, we excluded
such studies because unmeasured P. vivax exposure
and/or P. vivax antibody decay between measurements
may lead to misclassification and bias in estimates of
association. For measures of association, estimates ad-
justed for demographic variables and/or spatial confoun-
ders are reported where possible to reduce confounding.
Estimates adjusted for other anti-P. vivax antibodies are
not reported because antibody responses are typically
highly correlated, making it difficult to estimate their in-
dividual regression coefficients reliably [11]; in these
cases unadjusted estimates are reported.Data analysis
Data collection
Measures of association (odds ratio (OR), risk ratio
(RRs), incidence rate ratio (IRR), or hazard ratios (HR))
and their 95% confidence intervals (CIs) were extracted
or derived using data reported in the publications. Data
extraction was performed independently by two revie-
wers using a proforma. Contact with authors was estab-
lished through an initial email explaining the nature of
the systematic review and the information required, to-
gether with the proforma. If the corresponding author
did not respond within three email attempts, no further
action was taken. Where a study did not provide mea-
sures of association (or they could not be calculated
using the information provided) the study results were
used only for qualitative analysis.
Standardization of antibody measures
Measurement of antibody levels by ELISA does not pro-
duce a common metric between studies. Individuals can
be classified as ‘responders’ or ‘non-responders’ relative
to a negative control (unexposed sera) within each study.
Study-specific comparisons of these exposure variables
can then be pooled [11]. However, categories based upon
arbitrary cut-offs (including categories of responders
based on statistical rankings) cannot be pooled across
studies. For studies in which the antibody measures were
analyzed as continuous exposure variables, authors were
asked to reanalyze their data to provide a binary classifi-
cation of responders versus non-responders.
Standardization of malaria outcome measures
Studies were grouped according to the study design used
to examine the relationship between P. vivax antibodies
and P. vivax outcome. For cross-sectional and case–
control studies, OR was extracted or calculated, and for
cohort studies, RR, HR, and IRR were extracted or cal-
culated where possible, or unadjusted ORs were con-
verted to RR [14] (RR, HR, and IRR are hereinafter
denoted as RR). An RR/OR of 1 indicates that the risk/
odds of malaria is equal for those with (responders) and
those without (non-responders) antibody responses. Sep-
arate estimates were obtained for P. vivax detected by
light microscopy, PCR, and ligase detection reaction–
fluorescent microsphere assay (LDR-FMA). For meta-
analyses, estimates using different parasite detection
methods were combined. For studies in which multiple
estimates were reported for different detection methods,
the estimate reflecting the more commonly used method
was presented in the forest plot to enable comparisons,
and other estimates were presented in the text. Where
zero counts were present in 2 × 2 tables, a constant value
(0.5) was added to all cells to enable estimation of the
OR/RR.
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antibody response and P. vivax outcome. If antibody re-
sponses to the same antigen in the same population-
based study were reported in several publications, results
from the largest sample size were used. Separate esti-
mates were obtained for the OR/RR associated with the
PvCSP repetitive domain (VK210, VK247, P. vivax-like
alleles, NS1/81-V20 antigen, and VK210 and VK247
chimeric antigen), Pv merozoite surface protein (PvMSP)-
119, PvMSP-1 N-terminus, Pv apical membrane antigen
(PvAMA1) ectodomain, PvDBP (DBP region II AH, O, P,
and Sal 1 alleles, DBP regions II-IV, Sal 1 allele), PvMSP-9
(Block I and Block II repeats, Block II repeats, N-terminal
region), PvMSP-3α (full-length, N-terminal region, Block I
repeats, Block II repeats), PvMSP-5, P. vivax reticulocyte
binding protein (PvRBP1; the extracellular domain was
expressed as overlapping recombinant fragments), and
PvSERA4. Together with 95% CIs and P values, we inter-
preted a 20% relative difference in odds/risk of P. vivax
outcome to be a clinically meaningful difference between
antibody groups a priori, which is approximately half of
the observed efficacy of the P. falciparum RTS,S vaccine
in Phase III trials [15,16].
Synthesis of results: meta-analysis
A meta-analysis was performed for each antigen, strati-
fied by study design and P. vivax outcome. Where there
were two or more studies that could be combined, a
pooled estimate for each outcome was calculated using
either a fixed-effects or random-effects model. The
standard error of the natural logarithm (ln) of the RR/
OR was calculated using the formula: (ln(upper limit of
CI) –ln(estimate))/1.96. For fixed-effects models, pooled
effects estimates were weighted by the inverse of the in-
dividual study standard error. Where random-effects
models were specified, a between-study variance com-
ponent was incorporated into the study weights [17].
Between-study heterogeneity was measured with the I2
statistic, and represents the percentage of variation in a
pooled estimate attributable to between-study variability
[18]. Tests for significant between-study heterogeneity
were also reported, and were based on the weighted
sum of the differences between study estimates and the
overall pooled estimate; the statistic takes a χ2 distribu-
tion with degrees of freedom equal to the number of
studies minus 1 [17]. If heterogeneity was 30% or less, a
meta-analysis based on a fixed-effects model was speci-
fied; otherwise a random-effects approach was used.
Where the heterogeneity exceeded 75% and/or the het-
erogeneity test statistic was significant at P < 0.1, a
pooled effect was not estimated [18-21]. Owing to the
small number of studies included in the meta-analyses,
sensitivity analyses and assessments of publication bias
were not performed. All analyses were performed usingSTATA software (V11; StataCorp, College Station, TX,
USA).
Results
Identification and description of included studies
The database searches identified 1,411 records, of which
162 potentially relevant studies were identified, based
upon title and abstract. The full texts of these 162 stud-
ies were examined to determine whether they complied
with eligibility criteria: 114 did not meet the inclusion
criteria (see Additional file 3), 7 fulfilled the inclusion
and quality criteria (Figure 1), and 41 studies potentially
met inclusion and quality criteria. The authors of the 41
studies that potentially met inclusion and quality criteria
were contacted, yielding a further 11 studies that met in-
clusion and quality criteria, providing a total of 18 stud-
ies that were included in the review [22-39] (Figure 1).
Details of these 18 studies are shown in Table 1. Of
these 18 studies, 9 were cross-sectional, 6 were cohort
(4 of which also provided cross-sectional data), and 3
were case–control studies. One cohort study contributed
two publications [34,35], and one publication provided
data from two countries [22]. For the purpose of this re-
view, we shall refer to each publication as a study.
The included studies reported data from Brazil (n = 10),
Papua New Guinea (n = 4), Indonesia (n = 2), Thailand
(n = 2), and Turkey (n = 1) (Table 1). Sample sizes of
the included studies ranged from 61 to 432 study par-
ticipants, and the majority of studies included both chil-
dren and adults (4 included children only, 1 included
pregnant women only). Antibody responses to P. vivax
erythrocytic stage proteins were the main antigens studied
(PvMSP-1, n = 8; PvDBP, n = 4; PvMSP-3α, n = 2; PvMSP-
5, n = 1; PvMSP-9, n = 2; PvAMA1, n = 2; PvRBP1, n = 1;
PvSERA4, n = 1) and three studies examined antibody re-
sponses to the pre-erythrocytic stage protein PvCSP
(Table 1). No studies examined responses to gametocyte
antigens. Details of the recombinant antigens investigated
are outlined in detail (see Additional file 4). Total IgG re-
sponses were analyzed in 17 studies, with IgM and IgG
subclass responses being examined in 4 studies each
(Table 1). IgG1 and IgG3 subclasses were the predominant
IgG subclass responses in all studies [27,31,33,39,40] (see
Additional file 5). P. vivax infection was the most com-
monly examined outcome (n = 18), followed by symptom-
atic P. vivax infection (n = 5) and high-density P. vivax
infection (>150 parasites/μl, n = 1). Light microscopy was
used for P. vivax detection in the majority of studies
(n = 13), with four studies using PCR or microscopy
and three using LDR-FMA. For the purpose of the re-
view, all P. vivax infection was diagnosed by light micros-
copy unless stated otherwise. Results are presented for
each antigen stratified by study design: cross-sectional
and case–control studies, to identify markers of P. vivax
Database searches identified 1411 records
162 potential studies selected on the basis of title and abstract
7 studies met the 
inclusion criteria
7 studies met the 
quality criteria
Wrote to the authors of 41 studies 
requesting data that would meet 
inclusion and/or quality criteria
35 authors responded 6 authors had not responded 
after 3 email attempts
11 provided data that 
met inclusion and 
quality criteria
In total 18 studies (7 + 11) are included in the systematic reviewc




114 studies did not meet 
inclusion criteria






Figure 1 Flow chart of study identification. aFor details of excluded studies, see Additional file 3. bData not in format for re-analysis or data
not available. cThe characteristics of the included studies are given in Table 1.
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sponses that protect against P. vivax malaria.
Association between antibody responses to PvCSP repeat
region and P. vivax
Circumsporozoite protein (CSP), the predominant surface
protein of the pre-erythrocytic, sporozoite stage parasite,
has been implicated in the invasion of hepatocytes [41]. P.
vivax CSP contains a highly immunogenic central repeat
domain flanked by amino and carboxyl sequences, which
include highly conserved protein stretches (Regions I and
II-plus). Three main allelic forms of PvCSP, differing
mainly in the central repeat region, have been described:
VK210, VK247 [42], and P. vivax-like [43].
Cross-sectional and case–control studies
Two cross-sectional studies [28,39] and one case–control
study [38] examined the association of antibody responses
to the PvCSP repeat region and P. vivax infection. A
cross-sectional study in Brazil showed no association be-
tween IgG responses to the P. vivax-like allele of PvCSP
and odds of P. vivax infection (OR = 1.09, responders ver-
sus non-responders), but IgG responders to VK210 or
VK247 alleles had a non-significant reduction of 74% and
57% respectively, in the odds of P. vivax infection com-
pared with non-responders (Figure 2) [28]. By contrast, across-sectional study in Turkey showed a 2.4-fold increase
in the odds of P. vivax infection in IgG responders to
combined VK210 and VK247 alleles (compared with non-
responders, Figure 2) [39]. Similar associations were also
seen for IgM (OR = 3.8, 95% CI 2.06 to 7.01) [39]. A case–
control study in Thailand also showed a similar 2.4-fold
increase in the odds of P. vivax infection in IgG re-
sponders to the NS1/81-V20 antigen, which includes the
CSP repetitive domain (VK210 allele) compared with non-
responders (Figure 2) [38].
Association between antibody responses to PvDBP and
Plasmodium vivax
PvDBP is a leading vaccine candidate because invasion
of erythrocytes is largely dependent upon its interaction
with the Duffy blood-group antigen [44]. The conserved
N-terminal cysteine-rich rich region II (PvDBPII) consti-
tutes the receptor binding domain of PvDBP [45,46].
The full-length ectodomain of PvDBP, comprising re-
gions II to VI, is thought to correspond to the soluble
form of the protein [47].
PvDBP region II
Cross-sectional studies
The association of antibodies to PvDBP region II and P.
vivax infection was examined in one cross-sectional
Table 1 Characteristics of studies included in the systematic review by country
Author, year [reference] Region Age range, years Antibody response (type) Study design (n)a Plasmodium vivax outcomeb
Brazil
Fernandez-Becerra, 2010 [22]c Rio Machado DNS PvMSP-1NT, PvMSP-119 (IgG) CS (87) Pv infection (LM or PCR),
symptomatic Pv
Kano, 2012 [23] Presidente Figueiredo, Amazonas 9 to 44 PvDBPII-IV, PvMSP-119 (IgG) CS (432) Pv infection (LM or PCR),
symptomatic Pv
Lima-Junior, 2008 [24]d Rondonia 10 to 85 PvMSP-9RIRII, PvMSP-9RII, PvMSP-9NT (IgG) CS (282) Pv infection
Lima-Junior, 2011 [25] Rondonia 10 to 81 PvMSP-3αFL, PvMSP-3αNT, PvMSP-3αRI,
PvMSP-3αRII, PvMSP-3αCT (IgG)
CS (282) Pv infection
Lima-Junior, 2012 [26] Rondonia 11 to 89 PvMSP-119 (IgG) CS (277) Pv infection
Nogueira, 2006 [27] Portuchuelo, Rondonia DNS PvMSP-1NT, PvMSP-119 (IgG) Cohort (173) Pv infection
Oliveira-Ferreira, 2004 [28] Candeias do Jamari, Rondonia 12 to 74 PvCSP (VK210, VK247, P. vivax-like) (IgG) CS (61) Pv infection
Souza-Silva, 2010 [29] Acre 5 to 90 PvDBPII-IV (IgG) Cohort (CS)e (366) Pv infection, Pv infection (LM or PCR)
Tran, 2005 [30]f Colina and Ribeirinha, Rondonia 11 to 75 PvRBP1 (IgG) CS (87) Pv infection
Versiani, 2013 [31] Rio Pardo DNS PvMSP-1NT (IgG, IgG1, IgG2, IgG3, IgG4) Cohort (CS)
e (308) Pv infection, symptomatic Pv
Indonesia
Ak, 1998 [32] Robek 0 to 73 PvMSP-119 (IgG + IgM) CS (169) Pv infection
Woodberry, 2008 [33] Timika, Papua 3 to 60 PvMSP-5 (IgG, IgM, IgG1, IgG2, IgG3, IgG4) CC (340) Symptomatic Pv
Papua New Guinea
Cole-Tobian, 2009 [34] Madang 5 to 14 PvDBPII (AH, O, P, Sal 1), PvMSP-119 (IgG) Cohort
g (206) Pv infection, Pv infection (LDR-FMA),
Pv infection >150 parasites/μl
Fernandez-Becerra, 2010 [22] Madang 0.25 to 3 PvMSP-1NT, PvMSP-119 (IgG) CS (100) Pv infection (LM or PCR),
symptomatic Pv
King, 2008 [35] Madang 5 to 14 PvDBPII binding inhibitory antibodies Cohort (206)h Pv infection
Stanisic, 2013 [36] East Sepik 0.9 to 3.1 PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII,
PvMSP-3αCT, PvMSP-9NT, PvMSP-9RIRII (IgG)
Cohort (CS)e (183) Pv infection (LDR-FMA), symptomatic
Pv
Thailand
Fowkes, 2012 [37] Mae Sot, Tak 15 to 42i PvAMA1-ecto (IgG) Nested CC (467) Pv infection



















Table 1 Characteristics of studies included in the systematic review by country (Continued)
Turkey
Yildiz Zeyrek, 2011 [39] Sanliurfa 0 to 77 PvMSP-119, PvAMA1-ecto, PvSERA4, PvCSP
(VK210 and VK247 chimera) (IgG, IgM, IgG1,
IgG2, IgG3, IgG4)
CS (195) Pv infection
CC, case–control; CS, cross-sectional; DNS, did not state; LDR-FMA, ligase detection reaction–fluorescent microsphere assay; LM, light microscopy; PV, Plasmodium vivax.
aSample size refers to number of participants for whom serology was determined.
bP. vivax infection was determined by light microscopy unless otherwise stated.
cFernandez-Becerra, 2010 [22] reported studies performed in two countries and features twice in Table 1.
dThe studies described by Lima-Junior in 2008 and 2012 [24,26] were conducted in the same area, but the participants were different.
eCohort study with cross-sectional data also included.
fTran, 2005 [30] included data from two different study sites in Brazil.
gTreatment to re-infection study.
hKing, 2008 [35] reported estimates from the same treatment to re-infection study as that described by Cole-Tobian, 2009 [34].



















Figure 2 Forest plot of the association of PvCSP IgG responses with Plasmodium vivax infection. Estimates represent the odds of P. vivax
infection in IgG responders compared with non-responders. aData supplied by the original authors and estimate calculated by the current
authors; bpublished estimate. All estimates are unadjusted. Abbreviations: LM, light microscopy; W, weight.
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study was conducted at two study sites in Brazil, and
pooled OR showed that IgG responders to PvDBPII Sal
1 strain had higher odds of P. vivax infection compared
with non-responders (pooled OR using fixed effects
(feOR) = 2.82, 95% CI 0.71 to 11.15, I2 = 0%) (Figure 3)
[30] indicating that this antigen may be indicative of ex-
posure in this population.Cohort studies
A cohort study conducted in PNG by Cole-Tobian et al.
[34] revealed no evidence for an association between
IgG responses to any of the PvDBPII alleles studied
(AH, O, P, or Sal 1) and protection against P. vivax in-
fection detected by light microscopy (log(antigen units + 1);
HR ranged from 0.96 to 0.98, Figure 3) or LDR-FMA
(log(antigen units + 1); HR ranged from 0.92 to 1.02) [34].
However, IgG responders to PvDBPII (O, P, and Sal 1 al-
leles) had a lower risk of high-density P. vivax infections
(>150 parasites/μl) compared with non-responders (HR
ranged from 0.74 to 0.85) (Figure 3) [34]. In the same
Papua New Guinean cohort, King et al. [35] tested
plasma samples for their ability to inhibit binding of
PvDBPII to its receptor, Duffy antigen: individuals with
high-level (>90%) binding inhibitory activity had a 55%
reduction in risk of P. vivax infection detected by light
microscopy compared with those with low-level (<50%)
binding inhibitory activity (HR = 0.45, 95% CI 0.2 to
0.98) [35], providing further evidence of PvDBPII as a
target of protective antibodies.PvDBP region II-IV
Cross-sectional studies
The association of antibodies to PvDBP region II-IV
(PvDBPII-IV) and P. vivax infection was examined in
one cross-sectional study [23] and one cohort study
that also provided two sets of cross-sectional data
[29]. In a cross-sectional study, Kano et al. [23] found
no evidence for any association between IgG respon-
ses to PvDBPII-IV Sal 1 and P. vivax infection. One
study by Souza-Silva et al. provided data from two
cross-sectional surveys conducted in the same study
site in Brazil [29]. While the first (baseline) survey
provided no evidence for an association between IgG
responses to PvDBPII-IV Sal 1 and P. vivax infection
detected by light microscopy (OR = 1.10, 95% CI 0.43
to 2.82), the second survey showed that the IgG re-
sponders had increased odds of P. vivax infection
compared with non-responders (OR = 4.14, 95% CI
1.58 to 10.8) (Figure 3) [29]. Owing to significant hete-
rogeneity, these estimates were not combined (I2 = 67.6%,
P = 0.046).Cohort studies
Cohort data from Souza-Silva et al. [29] found a 22% in-
creased prospective risk of P. vivax infection (detected
by light microscopy or PCR) in PvDBPII-IV IgG respon-
ders compared with non-responders (RR = 1.22, 95% CI
0.73 to 2.06, Figure 3). These results suggest that P. vivax
infection during follow-up induced an anti-PvDBPII-IV
response.
Figure 3 Forest plot of the association of PvDBP IgG responses with Plasmodium vivax infection. Estimates represent the estimate of
P. vivax infection in IgG responders compared with non-responders, unless stated otherwise. For cross-sectional studies, the estimate is an odds
ratio; for cohort studies, it is a risk ratio. 1Colina study site; 2Ribeirinha study site; 3First (baseline) survey; 4Second survey. aEstimate supplied by
the original authors following correspondence; bdata supplied by the original authors and estimate calculated by the current authors; cestimate
calculated by the current authors from data in the paper; dpublished estimate. All estimates are unadjusted, with the exception of estimates from
Cole-Tobian et al. [34], which were adjusted for age. When I2 was ≤30%, meta-analysis based on a fixed-effects model was conducted. Estimates
for distinct alleles of PvDBPII were not combined in meta-analysis. Abbreviations: AU, antigen units; LM, light microscopy; RTQ-PCR, real-time
quantitative polymerase chain reaction; PNG, Papua New Guinea; W, weight.
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P. vivax
MSP-1 is conserved in all Plasmodium species, and is
thought to be essential for blood-stage development of the
parasite [48]. PvMSP-1 has a polymorphic N-terminus
(PvMSP-1NT) and a relatively conserved C-terminus [49].
Studies in P. falciparum have established that post-
translational proteolytic processing of PfMSP-1 generates
four fragments, including a C-terminal 42 kDa fragment,
which is further processed into a 19 kDa fragment that re-
mains on the surface of the merozoite during invasion
(PvMSP-119) [50-52].
PvMSP-119
A total of eight studies investigated responses to PvMSP-
119 and P. vivax outcomes [22,23,26,27,32,34,39,40].Cross-sectional studies
Four cross-sectional studies (providing five sets of data)
investigated the association between IgG responders to
PvMSP-119 and P. vivax infection (Figure 4) [22,23,26,39].
Meta-analysis revealed significant heterogeneity between
studies (I2 = 73.8%, P = 0.004), so a pooled estimate was
not reported. Increased odds of P. vivax infection (diag-
nosed by light microscopy or by LM in combination
with PCR) in PvMSP-119 IgG responders compared
with non-responders was found in Brazil (increased
odds of 81% [23] and 18% [26]), Turkey (447% increased
odds [39]) and Papua New Guinea (100% increased odds
[22]) (Figure 4). Conversely, data from another Brazilian
study [22] showed that IgG responders to PvMSP-119
had 48% decreased odds of P. vivax infection (compared
with non-responders) [22]. However, when these authors
Figure 4 Forest plot of the association of PvMSP-119 IgG responses with Plasmodium vivax outcomes. Estimates represent the estimate of
P. vivax infection in IgG responders compared with non-responders unless stated otherwise. For cross-sectional and case–control studies, the
estimate is an odds ratio; for cohort studies, it is a risk ratio. 1Meta-analysis of IgG responses to PvMSP-119 and odds of P. vivax infection (estimates
from cross-sectional studies) showed a high degree of heterogeneity (I2 = 73.8%, P = 0.004), so results were not pooled. aData supplied by the
original authors, and estimate calculated by the current authors; bestimate calculated by the current authors from data in the paper; cpublished
estimate. All estimates are unadjusted, with the exception of estimates from Cole-Tobian et al. [34], which were adjusted for age, and Noguiera
et al. [27], which were adjusted for geographical sector. When I2 was ≤30%, meta-analysis based on a fixed-effects model was conducted. AU,
antigen units; LM, light microscopy; PCR, polymerase chain reaction; PNG, Papua New Guinea; RTQ-PCR, real-time quantitative PCR; W, weight.
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laria at sites in Brazil and PNG, they found that IgG
responders to PvMSP-119 had 51% increased odds of
symptomatic P. vivax (feOR =1.51, 95% CI 0.71 to
3.23, I2 = 0%; Figure 4) [22]. Overall, these data, taken
together support IgG response against PvMSP-119 as
a marker of P. vivax infection in geographically di-
verse populations (Figure 4).
Two studies looked at IgM responses, as a marker of
recent exposure to PvMSP-119. Yildiz Zeyrek et al. [39]
showed that IgM responses were associated with higher
odds of P. vivax infection and of increased magnitude
compared with IgG (responders compared with non-
responders, OR = 48.8, 95% CI 16.3 to 146.1). One cross-
sectional study in Indonesia, which examined combined
IgG and IgM responses (and was therefore not in-
cluded in the IgG or IgM meta-analyses), showed a
71% reduction in the odds of P. vivax infection in re-
sponders versus non-responders (OR = 0.29, 95% CI
0.09 to 0.88) [32].Cohort studies
IgG against PvMSP-119 as a marker of protective im-
munity was assessed in two cohort studies [27,34]. No
evidence for an association between PvMSP-119 IgG
responses and P. vivax infection was found in Brazil
(responders versus non-responders; RR = 1.12, 95% CI 0.56
to 2.24) [27] or Papua New Guinea (log(antigen units + 1); light
microscopy: RR = 0.92, 95% CI 0.62 to 1.36 (Figure 4);
LDR-FMA: RR = 1.07, 95% CI 0.78 to 1.47) [34]. Although
Cole-Tobian et al. [34] found no association with P. vivax
infection in Papua New Guinea, they did observe a 31% re-
duced risk of high-density P. vivax infection (≥150 para-
sites/μl) (log(antigen units + 1); RR = 0.69, 95% CI 0.34 to 1.38).
PvMSP-1 N-terminus
Cross-sectional studies
The cross-sectional study by Fernandez-Becerra et al.
[22], conducted in Brazil and PNG, also investigated re-
sponses against the N-terminus of PvMSP-1 (PvMSP-
1NT) and found no evidence for an association between
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PvMSP-1NT and either P. vivax infection or symptomatic
P. vivax (feOR = 1.19, 95% CI 0.56 to 2.55, I2 = 0% and
feOR = 0.93, 95% CI 0.42 to 2.04, I2 = 0%, respectively;
Figure 5). By contrast, cross-sectional data from Versiani
et al. [31] in Brazil showed that IgG responders to
PvMSP-1NT had 4.2-fold increased odds of developing
symptomatic P. vivax (PCR- and light microscopy-
positive) compared with asymptomatic P. vivax malaria
(PCR-positive and light microscopy-negative) (OR = 4.23,
95% CI 1.40 to 12.76, Figure 5).
Cohort studies
Meta-analysis of two cohort studies in Brazil showed
that IgG responders to PvMSP-1NT had a 62% reduced
risk of P. vivax infection compared with non-responders
(feOR = 0.38, 95% CI 0.20 to 0.71, I2 = 0%, Figure 5)
[27,31] indicating that PvMSP-1NT may be a target for
protective immunity.
Association between antibody responses to PvMSP-3α
and P. vivax
Members of the P. vivax MSP-3 multigene family, includ-
ing PvMSP-3α, are structurally related to P. falciparumFigure 5 Forest plot of the association of PvMSP-1 N-terminus IgG re
estimate of P. vivax infection in IgG responders compared with non-respon
cohort studies, it is a risk ratio. 1Symptomatic and asymptomatic P. vivax-po
2symptomatic individuals who were positive for P. vivax were compared w
P. vivax; 3symptomatic individuals who were positive for P. vivax by both P
P. vivax by both PCR and LM. aEstimate calculated by the current authors fr
estimate calculated by the current authors; cpublished estimate. All estimat
et al. [27], which was adjusted for geographical sector. When I2 was ≤30%,
Abbreviations: LM, light microscopy; PNG, Papua New Guinea; W, weight.MSP-3, and are thought to associate with proteins an-
chored to the merozoite surface [53]. PvMSP-3α is
highly polymorphic, with polymorphisms clustered in
the N-terminal half of the central alanine-rich coiled-
coil domain (Block I repeats, PvMSP-3αRI) and the less
variable C-terminal half of the domain (Block II repeats,
PvMSP-3αRII). By contrast, the extreme N-terminal
(PvMSP-3αNT) and C-terminal (PvMSP-3αCT) domains
are relatively conserved [54].
Cross-sectional studies
One cross-sectional study in Brazil by Lima-Junior et al.
[25] and one cohort study in PNG by Stanisic et al. [36]
(which contributed both cross-sectional and cohort data)
investigated the association between antibody responses
to regions of PvMSP-3α and P. vivax outcomes. The two
cross-sectional studies gave opposing results and were
not combined (I2 > 75% and/or P < 0.01). Lima-Junior
et al. [25] showed around a 60% reduction in the odds
of P. vivax infection in IgG responders to PvMSP-3α
full-length (MSP-3αFL), PvMSP-3αNT, PvMSP-3αRI, and
around a 35% reduction for PvMSP-3αRII and PvMSP-
3αCT compared with non-responders (Figure 6). Con-
versely, Stanisic et al. [36] showed fold increases of betweensponses with Plasmodium vivax outcomes. Estimates represent the
ders. For cross-sectional studies, the estimate is an odds ratio; for
sitive individuals were compared with P. vivax-negative individuals;
ith asymptomatic individuals who were either positive or negative for
CR and LM were compared with individuals who were negative for
om data in the paper; bdata supplied by the original authors and
es are unadjusted, with the exception of the estimate from Nogueira
meta-analysis based on a fixed-effects model was conducted.
Figure 6 Forest plot of the association of PvMSP-3α IgG responses with Plasmodium vivax outcomes. Estimates represent the estimate of
P. vivax infection in IgG responders compared with non-responders. For cross-sectional studies, estimate is an odds ratio; for cohort studies, it is a
risk ratio. aData supplied by the original authors and estimate calculated by the current authors; bestimate calculated by the current authors from
data in the paper; cpublished estimate. All estimates are unadjusted, with the exception of estimates from cohort data from Stanisic et al. [36],
which were adjusted for age, season, spatial variation, and individual differences in exposure. Meta-analysis of responses to PvMSP-3αNT,
PvMSP-3αRI, PvMSP-3αRII, and PvMSP-3αCT, and odds of P. vivax infection (estimates from cross-sectional studies) showed a high degree of
heterogeneity (I2 > 75% and/or P < 0.1) so estimates were not pooled. Abbreviations: LM, light microscopy; LDR-FMA, ligase detection reaction-
fluorescent microsphere assay; PNG, Papua New Guinea.
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IgG responders to PvMSP-3αNT, PvMSP-3αRI, PvMSP-
3αRII, and PvMSP-3αCT, compared with non-responders
(Figure 6).Cohort studies
Although PvMSP-3α antibodies appeared to be a marker
of P. vivax infection in cross-sectional data from Stanisic
et al. [36], cohort data from the same study showed a
47% reduction in the risk of symptomatic P. vivax for
PvMSP-3αRII IgG responders and around a 20% riskreduction for IgG responders to PvMSP-3αNT, PvMSP-
3αRI and PvMSP-3αCT (Figure 6).
Association between antibody responses to PvMSP-5
and P. vivax
Case–control studies
The highly polymorphic PvMSP-5 contains potential
signal and glycosylphosphatidyl inositol (GPI) anchor
sequences and a single EGF-like domain near the
carboxyl-terminus [55]. PvMSP-5 has been localized to
the apical end of merozoites [56]. One case–control
study in Indonesia showed no association between IgG
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CI 0.62 to 2.04) responses to PvMSP-5 and odds of
symptomatic P. vivax [33].
Association between antibody responses to PvMSP-9 and
P. vivax
PvMSP-9 is associated with the surface of the merozoite
and contains a hydrophobic signal sequence, a highly
conserved N-terminal domain with a cluster of four cys-
teines, and a C-terminal region containing two species-
specific blocks of repeats, designated PvMSP-9RI and
PvMSP-9RII [57,58]. Recombinant proteins may repre-
sent individual blocks or both blocks (PvMSP-9RIRII).
PvMSP-9 N-terminus
Cross-sectional studies
Meta-analysis of three sets of cross-sectional data
[24,26,36] showed that IgG responses to PvMSP-9NT
were associated with a 76% increase in odds of P. vivax
infection compared with non-responders (pooled OR
using random effects reOR = 1.76, 95% CI 0.95 to 3.25,Figure 7 Forest plot of the association of PvMSP-9 IgG responses wit
infection in IgG responders compared with non-responders. For cross-secti
ratio. aData supplied by original authors and estimate calculated by the cu
the paper; cpublished estimate. All estimates are unadjusted, with the exce
adjusted for age, season, spatial variation, and individual differences in exp
P. vivax infection showed a high degree of heterogeneity (I2 = 77.5%, P = 0.
Abbreviations: LDR-FMA, ligase detection reaction-fluorescent microsphereI2 = 48.7%, Figure 7) suggesting that PvMSP-9NT is a
marker of exposure.
Cohort studies
One cohort study by Stanisic et al. [36] also provided
evidence for a protective effect of IgG responses to
PvMSP-9NT, with a 40% reduction in the risk of symp-
tomatic P. vivax (RR = 0.60, 95% CI 0.42 to 0.85).
PvMSP-9 block repeats
Cross-sectional studies
Three sets of cross-sectional data investigated the associ-
ation between IgG antibodies to a protein representing
the two blocks of repeats in PvMSP-9 (PvMSP-9RIRII)
and P. vivax infection [24,26,36]. In a Brazilian study in
2012, Lima-Junior et al. [26] showed that IgG respon-
ders to PvMSP-9RIRII had a 67% reduction in the odds of
P. vivax infection, compared with non-responders, but
in a 2008 study by these authors [24] in the same region,
PvMSP-9RIRII responders were found to have increased
odds of P. vivax infection (OR = 2.64, Figure 7). Similarh P. vivax outcomes. Estimates represent the estimate of P. vivax
onal studies, the estimate is an odds ratio, for cohort studies, it is a risk
rrent authors; bestimate calculated by the current authors from data in
ption of estimates from cohort data from Stanisic et al. [36], which were
osure. 1Meta-analysis of PvMSP-9RIIRII and PvMSP-9RII with odds of
012 and 87%, P = 0.006 respectively), so results were not pooled.
assay; LM, light microscopy; PNG, Papua New Guinea; W, weight.
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when IgG responses to PvMSP-9RII were examined
[24]. Stanisic et al. [36] showed that IgG responders
to PvMSP-9RIRII had a 33% increase in odds of P. vivax
infection detected by LDR-FMA (OR = 1.33, 95% CI
0.50 to 3.53). Meta-analysis of PvMSP-9RIRII responses
showed a high degree of heterogeneity in estimates
(I2 = 77.5%, P = 0.012), and a pooled estimate was not
reported.
Cohort studies
Cohort data from Stanisic et al. [36] showed no asso-
ciation between IgG responses to PvMSP-9RIRII and
prospective risk of symptomatic P. vivax (RR = 0.97, 95% CI
0.51 to 1.82; Figure 7).
Association between antibody responses to PvAMA1
ectodomain and P. vivax
Cross-sectional and case–control studies
PvAMA1 is a type 1 transmembrane protein present in
the microneme organelles of Plasmodium spp. A cross-
sectional study in Turkey, which included both chil-
dren and adults, investigated the association between


































Figure 8 Forest plot of the association of PvAMA1, PvRBP1, and PvSE
represent the odds of P. vivax infection in responders compared with non-
by original authors following correspondence; bdata supplied by original au
unadjusted, with the exception of the estimate from Fowkes et al. [37] whi
estimates from Tran et al. [30], which were adjusted for age. When I2 was ≤
Abbreviations: LM, light microscopy; W, weight.P. vivax infection, and found that total IgG responses
(OR = 4.62, 95% CI 2.17 to 9.82, Figure 8) and IgM
responses (OR = 2.22, 95% CI 1.06 to 4.67) were associated
with increased odds of P. vivax infection [39]. A similar
increase in the odds of P. vivax infection was seen in a
nested case–control study [37] of pregnant women in
Thailand (responders versus non-responders, OR = 4.25,
95% CI 2.08 to 8.70, Figure 8). PvAMA1 is therefore
associated with P. vivax exposure in geographically and
demographically diverse populations.Association between antibody responses to PvRBP1 and P.
vivax
Cross-sectional studies
PvRBP1 is a Type I integral membrane protein, which
was identified based on its ability to adhere preferentially to
reticulocyte-enriched populations of erythrocytes [59,60].
Together with PvRBP2, it is thought to form a complex at
the apical pole of the merozoite [59,61]. Meta-analysis of
two cross-sectional sets of data from two study sites by
Tran et al. [30] indicated that IgG responders to PvRBP1
had a 76% increase in odds of P. vivax infection detected
by light microscopy compared with non-responders













RA4 IgG responses with Plasmodium vivax infection. Estimates
responders. 1Colina study site; 2Ribeirinha study site. aEstimate supplied
thors and estimate calculated by the current authors. All estimates are
ch was adjusted for gravidity, trimester, and prophylaxis, and the
30%, meta-analysis based on a fixed-effects model was conducted.
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P. vivax
Cross-sectional studies
Serine repeat antigen 4 (SERA4) is the most dominantly
expressed member of the P. vivax SERA multigene
family, and its expression profile parallels that of PfSERA5,
a blood-stage vaccine candidate [62]. A single cross-
sectional study investigating the association between anti-
PvSERA4 responses and P. vivax infection showed that
both IgG and IgM responders had higher odds of P. vivax
detected by light microscopy compared with non-
responders (OR = 1.80, 95% CI 0.84 to 3.86, Figure 8 and
OR = 2.50, 95% CI 1.39 to 4.49, respectively) [39].
Discussion
In this systematic review, we aimed to identify immuno-
logical biomarkers of P. vivax infection and protective
immunity by standardizing estimates of the association
between P. vivax antibodies and P. vivax outcomes
across populations. We found a paucity of studies
investigating associations between antibody responses to
P. vivax antigens and risk of P. vivax, particularly cohort
studies, and studies conducted in the Asia-Pacific [1].
Although there was considerable heterogeneity between
studies, antibody responses to several antigens were as-
sociated with P. vivax infection and protective immunity
to P. vivax. However, this review highlights the need for
additional studies, and identifies several issues in the
interpretation and reporting of data from epidemio-
logical studies investigating immunity to P. vivax.
Studies included in the review represented diverse
geographical populations living in areas of varying P.
vivax endemicity. However, the geographical regions and
countries represented were limited. Half of the studies
provided data from the Asia-Pacific region, which repre-
sents 91% of the population at risk of P. vivax malaria
[1], but only four countries were represented (Indonesia,
Turkey, Thailand, and Papua New Guinea). The re-
maining half of the studies provided data from South
America, representing only 6% of the population at risk
of P. vivax malaria [1], but all were performed in Brazil.
This predominance of data from Brazil has implications
for the generalizability of findings to other P. vivax-
endemic regions in South America and the Asia-Pacific.
However, despite the population heterogeneity and the
considerable heterogeneity in estimates observed,
immunological markers of P. vivax infection could be
identified: IgG responses to PvCSP, PvMSP-119, PvMSP-
9NT, and PvAMA1 were associated with increased odds
of P. vivax in geographically diverse populations. Other
antigens were also shown to be markers of P. vivax
infection, but only in single populations (PvMSP-3α,
PvMSP-9RIRII, PvDBP, and PvRBP1). Serosurveillance
using PvCSP in Korea [63-67] and PvMSP-119 andPvAMA1 in Vanuatu [68], Cambodia [69], and Somalia
[70] has been employed to successfully map P. vivax
transmission, and data from this review support their
use in serosurveillance campaigns. However, this review
highlights that further studies, conducted in diverse
geographical settings and including additional antigens,
are needed to ensure the generalizability of results across
different populations with variable P. vivax transmission.
Protective immunity could only be examined in a
handful of cohort studies, all of which showed evidence
for protective blood-stage antibodies targeting PvMSP-
119, PvMSP-1NT, PvMSP-3α and PvMSP-9NT antigens
but only in single geographical locations. This was also
the case for PvDBP, a prime vaccine target (because of
its essential role in invasion) [44] that is currently in
Phase I trials [5]. PvDBP was examined in only two co-
hort studies (which looked at different regions) and
only Cole-Tobian et al. [34] showed evidence of allele-
specific PvDBPII protective immunity against high-density
parasitemia. Interestingly, no cohort study examined the
protective effect of antibody responses to either the pre-
erythrocytic antigen PvCSP or the gametocyte antigen
Pvs25. Both of these have previously been assessed in
Phase I trials [6,71-73], and PfCSP comprises the current
Phase III P. falciparum vaccine RTS,S, which has demon-
strated around 50% efficacy in young children and around
30% efficacy in infants [15,16]. This review shows that very
few antigens meet the pre-clinical criteria for prioritizing
candidate antigens (targets of protective immunity in
humans) for vaccine development, which is particularly
pertinent given the difficulties in meeting other in vitro
pre-clinical criteria (demonstrating essential/important
function, abundance, limited genetic diversity, inhibition
of parasite growth, protection in animal models of infec-
tion) [7] because of difficulties in maintaining P. vivax in
culture. In order to prioritize antigens for P. vivax vaccine
development, further studies including additional anti-
gens and established, clinically relevant end-points (for
example, allele-specific responses with allele-specific
end-points) are needed to provide valuable evidence for
the role of particular P. vivax antigens in protective
immunity.
The considerable heterogeneity observed in the esti-
mates of association, which meant that the magnitude
and the direction of effect estimates from different
studies varied considerably, was a major issue in the
meta-analyses, such that study estimates could not be
reliably combined in some instances. Methodological
diversity between studies may have contributed to the
heterogeneity: antibody responses were measured in dif-
ferent ways (alleles, antigen preparation); P. vivax infec-
tion was determined using detection methods of varying
sensitivities (PCR is more sensitive than light micros-
copy); and statistical methodology varied. Furthermore,
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adjusted for potential confounders, and within-study
bias may also have contributed to the heterogeneity ob-
served. Transmission micro-epidemiology within study
sites may be an important confounder, biasing the direc-
tion of effect in either way: individuals living in areas
with the highest P. vivax exposure will acquire both bio-
markers of exposure and protective immunity, but will
also be at increased risk of future P. vivax infections.
Study design may also be an important source of hetero-
geneity. The majority of studies were cross-sectional or
case–control studies in which antibody responses and P.
vivax outcomes had been determined at a single time
point, in those with or without P. vivax outcome.
Although we used this study design to identify immuno-
logical markers of P. vivax exposure, using data from a
single time point has the potential to also capture a de-
gree of protective immunity in the population. Indeed,
we observed these types of divergent associations for
several antigens, including studies by the same authors
using the same methodology both in different popula-
tions [22] and within the same population [24,26]. These
findings highlight the limitations of using cross-sectional
data, particularly when interpreting and comparing data
across populations with varying degrees of P. vivax
endemicity and immunity.
Differences in P. vivax transmission and exposure his-
tory will result in differential acquisition of immunity,
which will influence associations between P. vivax anti-
body responses and clinical outcomes. To reduce bias in
the systematic review, we excluded studies on transmi-
grants and studies in which the majority of the popula-
tion resided in a malaria-endemic area for a short time.
This bias was highlighted in two studies, which met the
respective inclusion criteria, both by Lima-Junior et al.
and performed in the same region of Brazil [24,26].
PvMSP-9 IgG responders were found to have increased
odds of P. vivax infection in 2008 [24], but decreased
odds of infection in 2012 [26]. However, the population
composition changed between the two studies: in 2008,
82% of participants were indigenous to the malaria-
endemic area, compared with only 59% in 2012 (J. Ferreira,
personal communication). This may explain, in part, the
differences observed, because in both studies, time of
residence in the malaria-endemic area was positively corre-
lated with the anti-PvMSP-9 response [24,26]. Differential
effects according to transmission were also anecdotally
observed: one study by Yidez-Zeyrek et al. in Turkey [39]
showed greater magnitudes of effect with IgM than with
IgG responses (PvMSP-119 and PvSERA4), indicating that
individuals living in this P. vivax-endemic area had limited
exposure to P. vivax. Interestingly, the ability of IgG to
serve as a marker of exposure in this study was more than
twice that of estimates from areas of higher P. vivaxtransmission (in Brazil and PNG), highlighting the poten-
tial for transmission intensity to influence results. Future
studies should be aware of the potential confounding intro-
duced by variations in P. vivax exposure and transmission
intensity, particularly those conducted in areas in which
P. vivax epidemiology is complicated by the presence of
migrant workers or transient communities, which is
common in P. vivax-endemic areas in South America
and South-East Asia.
This review aimed to be as comprehensive as possible,
and to identify all data by which an association between
P. vivax responses and P. vivax outcomes could be
examined. By contacting authors directly, we were able
to obtain data from a further 11 studies for which data
was not originally published. Commonly, these studies
were descriptive in nature, comparing antibody preva-
lence in P. vivax infected versus uninfected individuals,
with no quantification of the magnitude of effect. Conse-
quently, many included studies were not sufficiently
powered to detect a statistically significant association
between antibody responses and P. vivax outcomes.
Publication bias may also be an issue in the P. vivax
immunity literature, which could not be assessed in this
review because of the small number of studies in
each analysis.
In this review, we also included total IgG subclasses,
as well as IgG and IgM, to infer potential functional
mechanisms, with similar associations seen with sub-
classes as to total IgG (see Additional file 5). IgG1 and
IgG3 were the predominant subclasses to P. vivax anti-
gens, and may function by opsonic phagocytosis [74], or
by fixing complement. We found only one study that
utilized a functional assay: King et al. [35] showed that
binding inhibitory antibodies to PvDBPII were associated
with protection from P. vivax infection. The lack of a
continuous culturing system for P. vivax currently pro-
hibits the use of most types of functional assays, but will
clearly be important in future studies to determine the
relative role of various immune mechanisms in protec-
tion against P. vivax.
Conclusion and future directions
In the absence of an in vitro system, population-based
immunoepidemiology studies are pivotal to identify
P. vivax antigens associated with protective immunity
and exposure. This systematic review revealed antibody
responses to several antigens that were associated with
P. vivax infection and protective immunity. However,
observations were often made in a small number of
(sometimes single) studies, and further research is needed
to validate these findings. More research is needed not
only on P. vivax blood-stage antigens, but on sporozoite
and gametocyte antigens, which are important markers of
P. vivax transmission. Cohort studies are preferable,
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exposure and protective immunity. Future studies should
aim to represent diverse populations, and special conside-
ration in design and interpretation of findings should be
given to studies in populations that contain considerable
migrant sub-populations. Importantly, future studies
should appropriately and comprehensively report data,
and we have previously published guidelines to facilitate
correct reporting of malaria immunoepidemiology obser-
vational studies (Proposed guidelines of the reporting of
Malaria Immuno-epidemiology Observational Studies
(MIOS guidelines) [11]). Additional well-reported studies,
encompassing a wider geographical area, will provide a
solid evidence base for P. vivax antigens in the use of
vaccines and serosurveillance tools.
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